Exploring HMGB2 in hepatocellular carcinoma: charting new paths for diagnostic and therapeutic innovations

J Gastrointest Oncol. 2023 Dec 31;14(6):2668-2670. doi: 10.21037/jgo-23-934. Epub 2023 Dec 27.

Mohammed A Mashali^#^{1

2

3}, Nancy S Saad^#^{1

2

4}

¹ Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, OH, USA.
² Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, USA.
³ Department of Surgery, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.
⁴ Department of Pharmacology and Toxicology, Faculty of Pharmacy, Helwan University, Cairo, Egypt.

^# Contributed equally.

No abstract available

Keywords: Hepatocellular carcinoma (HCC); biomarkers; high mobility group box 2 (HMGB2); molecular pathways; therapeutic targets.

Publication types